Integra LifeSciences (NASDAQ:IART) Stock Rating Upgraded by Argus

Integra LifeSciences (NASDAQ:IART) was upgraded by equities researchers at Argus from a “hold” rating to a “buy” rating in a note issued to investors on Monday, MarketBeat reports.

Separately, Morgan Stanley started coverage on Integra LifeSciences in a report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective for the company. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $23.00.

Integra LifeSciences Trading Down 1.5 %

IART opened at $21.69 on Monday. The stock’s 50 day moving average price is $23.78 and its 200-day moving average price is $22.21. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -240.97, a P/E/G ratio of 0.73 and a beta of 1.23. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences has a one year low of $16.81 and a one year high of $35.45.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.12. The business had revenue of $442.65 million for the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same period last year, the company posted $0.89 earnings per share. On average, equities analysts forecast that Integra LifeSciences will post 2.45 EPS for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Large investors have recently bought and sold shares of the company. Quadrant Capital Group LLC raised its position in Integra LifeSciences by 5,960.9% during the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company’s stock worth $32,000 after buying an additional 1,371 shares during the last quarter. Sterling Capital Management LLC raised its holdings in shares of Integra LifeSciences by 821.7% during the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company’s stock worth $49,000 after purchasing an additional 1,931 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after purchasing an additional 2,800 shares during the period. Covestor Ltd boosted its holdings in Integra LifeSciences by 61.8% in the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company’s stock valued at $123,000 after purchasing an additional 2,071 shares during the last quarter. Finally, Empowered Funds LLC acquired a new stake in Integra LifeSciences during the 4th quarter worth about $180,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.